High blood pressure (BP) is an enormous global problem, and is especially challenging for low-and middle-income countries such as those of Latin America. Although developed countries have benefited from significant reductions in cardiovascular and cerebrovascular disease in recent decades, comparable reductions have not been achieved in Latin America. In fact, the prevalence of high BP is increasing in many Latin American countries, and the situation will worsen without definitive efforts to correct it. The growing preponderance of hypertension and chronic diseases, coupled with expected increases in population growth, present a mounting threat to Latin American economies. This report provides a comprehensive overview of the burden of high BP throughout Latin America, and presents recommendations for change. The dismal observations warrant a call to action for improved control of high BP and other cardiovascular risk factors across Latin America. Achieving these ambitious goals will require collaborative efforts by many groups, including policymakers, international organizations, healthcare providers, schools and society as a whole.
Introduction
Latin America is a heterogeneous region with wide ethnic, cultural, and socioeconomic diversity. The region generally is considered to comprise 20 low-and middle-income countries in North America, Central America, South America, and the Spanish-speaking Caribbean.* It is a diverse region in terms of socioeconomic development and health outcomes; infant mortality rates range from almost 10% in some areas in Bolivia to less than 1% in Cuba, Costa Rica, and Chile [Pan American Health Organization, 2007] . Major healthcare problems related to both equity and efficiency exist in most countries in Latin America. Their pluralistic and fragmented healthcare systems affect the delivery of equitable health services because of poor coordination among the healthcare provider subsectors, inequality in the levels of financing and quality of care, and barriers to access to services (mainly economic) for some population groups.
The increasing burden of chronic diseases in developing countries Despite these considerations, the overall health indicators of the Latin American population have improved markedly in the last 50 years and this trend is continuing. In particular, sharp reductions in the incidence of communicable and infectious diseases have resulted in significant increases in average life expectancy. Although this news is obviously good, it presents new health challenges as the clinical management burden shifts from acute (less expensive, less complicated) to chronic (more expensive, more complex) disease. Chronic diseases are increasing in developing countries, and cardiovascular disease (CVD) accounts for 17.7 million annual deaths around the world, constituting 11% of estimates for the global burden of disease. Moreover, for the 4 billion people who live in middle-income or rapidly changing countries, it represents the fastest-growing burden of disease. The increased burden of chronic diseases that developing countries are now facing is compounded by the fact that the rates of infectious and communicable disease are still higher than in the developed world. Thus, areas such as Latin America face a unique 'double burden of disease' [Sen and Bonita, 2000] , which is anticipated to worsen.
Projections for increased deaths due to chronic diseases Chronic diseases, mainly CVD, cancer, chronic respiratory diseases, and diabetes, were estimated to cause more than 60% of all deaths in 2005, and more than 80% of these occurred in low-and middle-income countries [Strong et al. 2005 ]. It has been projected that in 2015, 41 million people will die from chronic diseases unless concerted action is taken to prevent and treat such conditions [Strong et al. 2005] . Accordingly, the World Health Organization (WHO) recently re-emphasized the importance of chronic diseases as a neglected global health issue, noting that reducing the global death rate attributable to chronic disease by just an additional 2% every year from 2005 to 2015 would result in the prevention of 36 million premature deaths [Strong et al. 2005; WHO, 2005] . For the 23 developing countries surveyed in a recent WHO study [WHO, 2005] , which included Argentina, Brazil, Colombia, and Mexico, the number of deaths due to chronic disease is projected to increase by approximately 18%, from 23.1 million in 2005 to 27.2 million in 2015 [Abegunde et al. 2007] . Approximately 50% of these deaths will occur in people younger than 70 years, compared with only 27% in high-income countries, adding to the tremendous socioeconomic burden and loss of productivity. This figure will rise to 53% in 2030, and death and disability due to chronic diseases will account for nearly 60% of the total DALYs* (disability-adjusted life years) lost due to death and disability from all causes. According to the WHO study [WHO, 2005] , doing nothing to reduce the risk for chronic disease in the 23 countries studied will result in the loss of approximately US$84 billion in economic production ($13.5 billion in the four Latin American countries studied) [Abegunde et al. 2007] . Reducing chronic disease rates by an additional 2% each year throughout the next decade not only would save 24 million lives but also would save an estimated $8 billion nearly 10% of the projected losses ($1.4 billion in the four Latin American countries studied).
The impact of high blood pressure (BP) and CVD on morbidity and mortality CVD is estimated to be the leading cause of death, accounting for approximately 30% of deaths worldwide and an equivalent level of lost DALYs. Despite the fact that age-adjusted cardiovascular death rates have declined in some developed countries over the past few decades, the rates of CVD have increased greatly in low-and middle-income countries, with about 80% of the burden now occurring in these countries . It is estimated that mortality due to ischemic heart disease and cerebrovascular disease will increase by approximately 145% among men and women from 1990 to 2020 in Latin America, compared with an increase of 28% for women and 50% for men during the same period in developed countries [Yusuf et al. 2001] .
In a recent Lancet publication, the International Society of Hypertension reported estimates of the disease burden related to high BP [Lawes et al. 2008] . Estimates were based on the population attributable risk or the proportional reduction in average disease risk over a specified period that could be achieved by eliminating high BP from the population if other risk factors remained unchanged. The authors concluded that 7.6 million premature deaths (13.5% of the global total) in 2001 could be attributed to elevated BP, which is responsible for 54% of strokes, 47% of ischemic heart disease, 75% of hypertensive disease and 25% of other CVDs. Eighty percent of the burden of BP-attributable diseases occurred in low-and middle-income countries, Latin America included, with attributable death rates 1.5-to 2-fold higher in low-or middle-income regions compared with high-income areas. A greater proportion of this disease burden occurred in younger people. About half the burden was among people with systolic blood pressure (SBP) of less than 145 mmHg. In commentary accompanying this publication, several distinguished experts on hypertension noted that the global expenditure on antihypertensive treatment is about US$50 billion each year *DALY (disability-adjusted life-year) is a summary measure that combines years of life lost due to premature death and years of life lived with disability. Thus, 1 DALY represents 1 lost year of healthy life. [MacMahon et al. 2008] . Of that total, more than 90% is spent in high-income countries. The experts also noted that middle-and low-income regions have a five-fold greater burden of disease, but have access to less than 10% of global treatment resources.
Strategies and programs to manage cardiovascular conditions have been created and implemented in well-developed countries, but not in most developing countries. This is unfortunate because at least 75% of CVD may be explained by readily modifiable lifestyle factors, such as unhealthy diet (e.g. excessive salt intake), low physical activity and use of tobacco [WHO, 2002; Murray et al. 1996] . Suboptimal control of BP and high cholesterol also contribute to the burgeoning problem of CVD. The WHO has estimated that 50% of CVD among people over age 30 years can be attributed to elevated BP, 31% to high levels of cholesterol, and 14% to use of tobacco, for a combined risk that accounts for 65% of all CVD events [WHO, 2002] . The WHO also has determined that the implementation of effective strategies to reduce salt intake, lower cholesterol, and reduce body mass index (BMI) could result in a very substantial reduction in the risk of cardiovascular events, in the order of 50% or more [WHO, 2002] . High BP, generally defined as a BP > 140/90 mmHg, is the leading modifiable risk factor for death and disease for adults worldwide [Lopez et al. 2006 ]. In 2000, 26% of the world's population had high BP, and this is expected to increase to 39% (1.56 billion persons) by 2025 [Kearney et al. 2005 ]. The poorest economic areas will bear the brunt of this anticipated increase, such that by 2025, 75% of affected people will live in these countries [Kearney et al. 2005] .
The need for greater emphasis on development and implementation of cardiovascular health programs Recently, Ortega-Bolanos conducted a systematic review of the medical healthcare literature to identify the most effective community interventions around the world for managing high BP and for promoting BP-related interventions and communication [Ortega-Bolanos, 2008] . Of the 1041 articles identified, only 11 fulfilled the levels of evidence and evaluation necessary for producing recommendations. The author concluded that the available evidence concerning effective, culturally suitable programs for promoting a reduction in the risk factors for high BP is limited despite increasing awareness of the great need for risk-reducing community interventions that are directed toward special populations and tailored to cultural characteristics. Perhaps this is not surprising. Because of socioeconomic heterogeneity, pluralistic and fragmented healthcare systems, and disparity in current efforts to improve healthcare outcomes among the countries in Latin America, it is challenging to perform a full assessment of the prevalence and impact of high BP, and estimates cannot always be extrapolated from one area to another. Furthermore, given that some areas of Latin America are developing more rapidly than others, it becomes difficult to gauge the future impact of disease; changes in diet and lifestyle (such as increased consumption of prepackaged high-calorie foods and beverages, and more sedentary behavior) influence the prevalence and severity of high BP and other risk factors for chronic disease. Despite these considerations, and perhaps because of them, undertaking a comprehensive analysis of the increasing hazard presented by high BP in this region is especially timely. Such an analysis will be essential to inform the health-policy decisions needed to reduce the chronic disease burden due to high BP and develop plans to create the healthcare and social services needed to implement community as well as risk-based strategies to manage high BP at both the population level and the individual level.
In 1995, to address the increasing burden of noncommunicable diseases in Latin America, especially CVD and its risk factors, the Pan American Health Organization (PAHO) launched the Countrywide Integrated Non-communicable Diseases Intervention Programme in Latin America/Conjunto de Acciones para la Reducció n Multifactorial de Enfermedades No Transmisibles (CINDI/CARMEN) [Organizacion Panamericana de la Salud, 1997] . CARMEN was inspired by the CINDI program, sponsored by the European Regional Office for the WHO. Twenty countries in Europe and Canada participate in this network of integrated community national projects to prevent and control chronic diseases [Moiso, 1996] . CARMEN has been built from the CINDI program, taking into account the specific characteristics of countries in Latin America and the Caribbean. A handful of community-based programs under the CARMEN umbrella have been implemented in Argentina [Moiso, 1996] , Chile [Vega et al. 1999] and Colombia [Bautista et al. 2006 ], among others, with promising results.
Call to action
Political action is required in all countries in Latin America to establish awareness of high BP, and to improve its identification, management, and control. In addition to developing health policies, there is an urgent need to implement policies and education programs now, recognizing that the prevalence of high BP is increasing and that the situation will worsen without definitive efforts by society and policymakers to encourage greater understanding of, and attention to, modifiable risk factors.
. More concerted public action must be taken to discourage high-risk lifestyle factors, such as obesity and unhealthy diet, which are associated with modernization. . Schools in both developed and developing countries should actively promote cardiovascular health programs, including health education and physical activity programs, as well as provide meals with good nutritional value while limiting the amounts of foods with poor nutritive value and excessive levels of sugar and salt. . Public policy must more strongly advocate and encourage healthy nutrition, reduced salt intake, greater physical activity, and prevention of obesity from birth. . There is a need for community-based programs that promote a healthy lifestyle, encouraging home cooking, limited intake of prepackaged 'fast' food and non-nutritive snacks and beverages, reducing sodium intake, avoiding smoking, limiting alcohol intake, limiting the time spent on sedentary activities (such as watching television and computer gaming), and increasing physical activity. . Policies are needed to limit the direct marketing of tobacco, alcohol and non-nutritional foods (such as sweets, soft drinks, and chips) to children. . An aggressive public policy initiative is needed to facilitate and improve the medical community's ability to identify people at risk for cardiovascular events and provide timely and cost-effective treatment of high BP through different actions. . Governments, insurers, and other payers must acknowledge the magnitude of the problem of high BP, and increase funding to ensure appropriate investigation and treatment and thus improve long-term outcomes.
. The charitable community, intergovernmental organizations, nongovernmental organizations, civil society groups, health professionals, the private for-profit sector and the research community must unite against the threat of high BP.
. Efforts must be made to better establish clinical practice guidelines that take into account the specific cultural and social attitudes, values, and beliefs of Latin American patients.
Focus must be placed on the implementation of and adherence to these treatment guidelines, minimizing the gap between guidelines and practice. Physician follow-up of patients must become a top priority.
. A concerted effort must be made to increase availability and access to medical care for the diagnosis and treatment of high BP and to align these efforts with programs that address the management of other cardiovascular risk factors. . Efforts are needed to increase education on healthy lifestyle choices, the dangers of high BP, and the need for adequate medical care.
Unless the problem of high BP in Latin America is given the greater attention it deserves by policymakers, healthcare providers, schools, and society as a whole, it will continue to grow, further contributing to the current worldwide epidemic of CVD and its burden on society. It is our duty to take action at international, regional, and national levels to prevent this.
High BP as a global health epidemic Several studies have reported prevalence estimates of high BP in the United States of around 30% and European countries around 45% [Ong et al. 2007; Wolf-Maier et al. 2003 ]. BP increases with age in developed communities with increases of 20 mmHg in SBP and 10 mmHg in diastolic BP (DBP) between the ages of 30 and 65 years [Kannel, 1996] . The disproportionate rise in SBP is attributed to the loss of arterial compliance that occurs with age [Kannel, 1996] . The National Health and Nutrition Examination Survey (NHANES) conducted in the United States, found other factors that increase the risk of high BP include a genetic propensity, smoking, poor diet, increasing BMI, race (e.g. the US prevalence is higher in blacks than in whites), and being less well educated [Ong et al. 2007 ].
In 2001, approximately 7.5 million deaths from chronic disease worldwide were attributed to high BP [Lopez et al. 2006 ]. Even at BP levels below the definition of hypertension, the risk of CVD is increased. For example, the WHO estimates that 62% of cerebrovascular disease and 49% of ischemic heart disease is attributable to SBP > 115 mmHg [WHO, 2002] . In the US Framingham Heart Study, prehypertension (BP 130139/8589 mmHg) was associated with more than a two-fold increase in CVD risk compared with normal BP (<120/80 mmHg) [Vasan et al. 2001] . The presence of additional risk factors compounds this risk for adverse cardiovascular events (coronary artery disease, stroke, cardiac failure and peripheral vascular disease) associated with high BP [Whitworth, 2003; Kannel, 1996] . , 1998 ]. All have included data on the prevalence and distribution of high BP according to the risk factors explored. The importance and relevance of these countrywide surveys cannot be overlooked. In effect, individual studies and subnational surveys have not always provided valid information because they are subject either to selection bias (e.g. when selection of the individuals or populations is not conducted randomly) or to 'regression dilution bias' which occurs in small surveys that use a direct measure of BP instead of self-report measures. The latter bias occurs when risk-factor associations are calculated from 'one-off' measures of BP (i.e. measurements taken only on a single occasion) rather than 'usual' BP [MacMahon et al. 1990 ]. While it is not possible to eliminate regression dilution bias in cross-sectional surveys, no matter how large the surveys are, it is quite possible to reduce the magnitude and extent of this bias in larger samples (such as those used in national surveys) because the larger the study, the greater the 'offsetting' effects.
Prevalence of high BP in Latin America
All recent national surveys in Latin America show that high BP is an important risk factor for CVD. However, a wide variation in the prevalence estimates among adults has been observed in these countries, ranging from 12.3% in Colombia [Ministerio de Salud, 1998 ] to 34% in Argentina [Ministerio de Salud de la Nacion, 2006] . The most recent study to assess the prevalence of high BP in Latin America was the Cardiovascular Risk factor Multiple Evaluation in Latin America (CARMELA) study [Schargrodsky et al. 2008 ]. This study included 11 550 adults living in seven major cities across Latin America, all but one being capital cities. The mean age of participants was 44.5 years. The prevalence of various cardiovascular risk factors and the distribution of Framingham risk scores are shown in Figure 1 . Two clusters of data were identified: the prevalence of high BP was markedly higher in Barquisimeto, Buenos Aires, and Santiago than in Lima, Mexico City, Bogotá and Quito. Overall, one in seven persons living in these Latin American cities had at least one risk factor for a cardiovascular event.
INTERHEART was an international case-control study to evaluate the impact of conventional and emerging cardiovascular risk factors on acute myocardial infarction (MI) around the world [Lanas et al. 2007; Yusuf et al. 2004] . A total of 52 countries participated in the study, six of which were from Latin America (Argentina, Brazil, Colombia, Chile, Guatemala and Mexico). Worldwide, 15 152 patients with a history of acute MI and 14 820 control individuals were included [Yusuf et al. 2004 ]. The prevalence of high BP among the controls in Latin American countries was 40% higher than that of controls in the rest of the world (29.1% compared with 20.8%) [Lanas et al. 2007 ]. National and regional prevalence data have also been reported, as shown in Table 1 . Below are specifics for selected Latin American countries, while other countries are discussed in additional references [Blondin and Lewis, 2007; Cerdas, 2006; McCullough et al. 2006; Ordunez-Garcia et al. 2006; Goldstein, et al. 2005; Garcia-Palmieri et al. 2005; Ordunez et al. 2005; Araya and Padilla, 2004; Anselmi et al. 2003; Hollenberg et al. 1997 ].
Argentina
Chronic diseases, led by CVD, account for more than 50% of overall morbidity and mortality in Argentina. CVD accounted for 32.8% of all deaths in 2001 (93 972 of 285 941), with the age-adjusted incidence of coronary heart estimated at 360/100 000 for men and 80/100 000 for women; the age-adjusted incidence of stroke Low (<10% 10-y risk)
Intermediate ( Therapeutic Advances in Cardiovascular Disease 3 (4) was estimated at 120/100 000 for men and 75/100 000 for women, a pattern seen in uppermiddle-income countries [Direcció n de Estadísticas e Informació n, 2002]. In 2005, the Ministry of Health conducted a multistage probabilistic national survey of risk factors in a sampling of 50 000 households from all districts, which was considered representative of the Argentine population at large [Ministerio de Salud de la Nacion, 2006]. Of the 80% of subjects who checked their BP in the previous 2 years, 34% reported at least one elevated measure (31.6% in men and 36.8% in women). The incidence of elevated BP in this group appeared to increase with age, from 13.7% in subjects younger than 24 years to almost 60% in those older than 60. Even though the prevalence of high BP among these subjects did not differ significantly from district to district (rates ranged from 29.9% in the federal district to 41.5% in La Rioja), the poorer provinces had higher rates than the wealthier provinces. The prevalence of other cardiovascular risk factors in hypertensive and normotensive subjects is shown in Figure 2 . Except for smoking, the prevalence of other risk factors for CVD was significantly higher among individuals with high BP relative to those without it.
Another prevalence study, conducted from 1995 to 1998 in people aged 20 years and older (n ¼ 2397) living in four cities in central Argentina (Dean Funes and Oncativo, Có rdoba province; Pehujó, Buenos Aires province; Venado Tuerto, Sante Fé province), found the overall prevalence of high BP to be 36% (range between cities, 28% to 44%) [de Sereday et al. 2004 ]. The prevalence of high BP increased with age, to 75% in people over 60 years of age. The prevalence of other cardiovascular risk factors was also high: 26% of participants were obese and 31% had hyperlipidemia.
Brazil
In 2006, a multistage probabilistic phone survey administered to more than 57 000 households living in the federal district and the capitals of the 26 Brazilian states was undertaken, with more than 50 000 interviews completed [Ministerio da Saude, 2007] . The prevalence of high BP was higher among women than men (24.4% and 18.4%, respectively). Prevalence increased with age, from 5% (younger than 24 years) to more than 50% (older than 64 years). Regional prevalences ranged from 15.1% (Palmas) to 24.9% (Recife).
Other studies have estimated the prevalence of high BP in the various regions (including people from urban areas and from different Table 1 . Hypertension rates in Latin America. These data come from different national or regional sources than are presented in the text and thus may differ [Sanchez et al. 2009 ].
Country
Hypertension prevalence (%) socioeconomic classes) of Brazil (Table 2) . Not surprisingly, there is a wide range in the prevalence of high BP among regions, ranging from 23% to 52% depending on the population studied. Rates tended to be lower in studies that included a wide range of ages, but in general, the prevalence of hypertension was higher among older people and those with coexisting cardiovascular risk factors. These studies demonstrated the following key points:
. , 1998 ]. The survey results indicate that high BP was more common among women than men, and the prevalence correlated with increasing age, low level of education and socioeconomic strata, similar to the findings of other regional surveys. Hypertensive disease ranked fourth in mortality tables among people older than 65, with a rate of 243 per 100 000 [Ministerio de Salud, 2003 ].
In a cross-sectional study conducted in 2001 in 2989 people aged 15 to 64 years from Bucaramanga (population 560 000 people), the overall prevalence of high BP was 9.9% in women and 8.8% in men [Bautista et al. 2006 ]. The rates increased to 32.8% among subjects 50 to 59 years of age and to 52.2% among those aged 60 to 64 years. These increases paralleled increases in obesity and dyslipidemia, with women exhibiting higher rates in all categories. For example, the rate of obesity was 7.6% among men aged 60 to 64 years but 36.3% among women in the same age group.
Mexico
Several population-based surveys have been conducted to understand the impact of high BP in Mexico, where the prevalence increased from The last national survey of health and nutrition (ENSANut, 2006) was a multistage probabilistic survey that sampled 48 600 households across all states in the country [Secretaria de Salud, 2008] . The prevalence of high BP in the population over 20 years of age was 30.8% and was slightly higher among men (31.5%) than women (30.6%). These rates were similar to those reported in the previous national nutrition and health survey in 2000 (ENSA, 2000) [Valdespino et al. 2003 ]. Interestingly, the proportion of women previously diagnosed with high BP was higher than that of men (18% versus 11%, respectively), whereas the majority of men were diagnosed by the survey. Fifty percent of men and 60% of women older than 60 years had high BP.
Panama
The Kuna Indians of Panama, who live on islands off the coast, are a unique group of people characterized by an exceedingly low prevalence of high BP, including age-related increases in SBP and DBP [Hollenberg et al. 1997 ]. However, this low prevalence is thought to be related to environmental rather than genetic factors, because the Kuna Indians who have migrated to urban Panamanian areas have a higher rate of hypertension, as well as greater mean BP and weight, compared with the population residing in the islands (Table 3 ) [McCullough et al. 2006; Hollenberg et al. 1997 ]. In a comparative evaluation of 316 Kuna adults aged 18 to 82 years, the prevalence of high BP was 2.2% among indigenous Kuna Indians but 11% among those living in Panama City, and more than 45% of the latter population over 60 years of age had high BP [Hollenberg et al. 1997 ].
Uruguay
The adult prevalence of high BP was 28.5%, which correlated with BMI [Diaz, 2002] .
Venezuela
A 2000 survey of 3640 men and 3784 women over 20 years of age, designed to represent the Venezuelan population at large, showed the prevalence of high BP to be 29% in women and 45% in men [Sulbaran et al. 2000 ]. Rates were related to age and BMI. Data obtained in 19992000 from a population-based study of risk factors for coronary heart disease noted higher rates of high BP for black Hispanic men (67%) relative to mixed Hispanic men (52.3%), and higher rates for black Hispanic women (39%) than mixed Hispanic women (30%) [Ryder et al. 2007 ]. Trends were similar for other cardiovascular risk factors, including elevated fasting blood glucose, abdominal obesity, and high plasma levels of high-density lipoprotein cholesterol (HDL-C).
Lifestyle trends and other contributors to hypertension in Latin America
The rapid social and financial advances in Latin America are profoundly effecting disease burden, as is shown by the shift from acute to chronic disease ( Figure 3) [CONAPO, 2008; INEGI 2001 INEGI , 1990 . For example, in 1970 the main causes of death in Mexico were influenza and diarrhea, but by 2005 these were diabetes and ischemic heart disease.
The development of risk factors that contribute to chronic disease burden can be attributed largely to environmental, socioeconomic, and cultural causes (Figure 4 ). Furthermore, it is well known that lifestyle changes develop at different rates in the various geographic regions of Latin America. Several studies have examined the impact of such changes on the prevalence of hypertension and other cardiovascular risk factors. For example, the Mirame! program was launched in Chile in 1993 to promote a healthy lifestyle in fifth and sixth graders from five selected municipalities of the metropolitan region [Berrios et al. 2004] . Tobacco use and alcohol consumption were monitored to determine the success of the program. A baseline survey was done in 1993 and repeated in 1996 in both groups. The incremental cost per child who avoided alcohol consumption was US$112 This study showed that it is possible to apply health-promotion interventions in schools, with good costeffectiveness in the short term.
Rural-to-urban migration
In developing countries, the percentage of individuals living in urban areas increased from 13% in 1970 to 22% in 1994 and is expected to double to 44% by 2025 [Yusuf et al. 2001 ].
Rural-to-urban migration is associated with the adoption of less-healthy lifestyle habits that likely contribute to the burden of disease, such as a marked increase in the intake of energy-rich foods, with a corresponding decrease in consumption of fruits and vegetables and a reduction in physical activity [Dirks et al. 2006b; Yusuf et al. 2001] . In a study comparing Guatemalans (n ¼ 473) aged 19 to 29 years still living in their birth village with those who moved or commuted to work, migration to a city increased sedentary lifestyle and undesirable eating habits, and promoted overweight status and obesity [Torun et al. 2002] . A total of 79% of urban men were sedentary, compared with 27% of rural men (p < 0.001). Urban men also were significantly heavier (mean weight 62.4 kg for migrants versus 58.4 kg for nonmigrants; p < 0.05) and had lesshealthy blood lipid profiles than rural men. Adoption of different cultural lifestyles after migration to urban areas also influences the development of risk factors. For example, the prevalence of metabolic syndrome is significantly higher in Japanese-Brazilian men in Brazil (37.5%) than in native Japanese men (21.4%) or Japanese-Brazilian men in Japan (25.3%) (p < 0.05 for both comparisons) [Schwingel et al. 2007 ].
Dietary factors
The Kuna Indians of Panama provide a unique opportunity to explore the relationship between environmental factors and increases in BP, because they are essentially free of high BP and CVD until they migrate from their indigenous islands to cities [Hollenberg et al. 1997 ]. Higher rates of stress have been reported for Kuna who migrated to Panama City relative to those who remained in their island community, although BP levels did not correlate with stress [Hollenberg et al. 1997 ]. It is more likely that major differences in food consumption between rural and urban Kuna are responsible for the change in BP levels. Nutritional and epidemiologic transitions in Mexico have been characterized using data from several sources (age-adjusted standardized mortality rates, national nutrition surveys and National Income and Expenditure Surveys) [Rivera et al. 2002] . Between 1980 and 1998, deaths due to acute MI, diabetes, and hypertension increased by 53%, 62%, and 55% (respectively), which paralleled a 78% increase in obesity. According to available data on dietary intake and food purchase, fat intake increased between 1988 and 1999 while protein intake decreased. Purchases of foods containing sugars and refined carbohydrates increased 10% from 1984 to 1999. Purchases of cereals and tortillas declined steadily, but purchases of soda increased. These observations do not conclusively establish a relationship between food intake and these chronic diseases, but nevertheless highlight the association with obesity.
Other risk factors
Individuals with high BP often have other risk factors for CVD. In Uruguay, for example, 74% of people with high BP were obese (BMI > 25 kg/ m 2 ) [Diaz, 2002] . In Rio de Janeiro, 50% of patients with high BP were obese, and 51% of patients with diabetes also had high BP [de Sereday et al. 2004 ]. In Mexico the prevalence of hypertension is 48.2% in people with diabetes and 28.1% in those without diabetes. The prevalence is 48% among the obese population and 24.8% among the nonobese [Secretaria de Salud 2008 , 1994 Valdespino et al. 2003; Velazquez, et al. 2002] . This combination of risk factors increases the risk of cardiovascular events [Bautista et al. 2006 ]. High BP is a strong predictor of the metabolic syndrome, a disorder characterized by the combination of three of five risk factors abdominal obesity, low plasma HDL-C, triglyceridemia, high BP, and impaired glucose tolerance [Royer et al. 2007 ]. The prevalence of metabolic syndrome components is exceedingly high among postmenopausal Latin American women from low socioeconomic groups: 88%, 62%, and 35% of women have at least one, two, or three components, respectively; 48% have high BP [Royer et al. 2007 ].
Children and adolescents
Of particular concern in developed nations is the increasing prevalence of obesity, diabetes, and hypertension among children and adolescents. Similar trends are now being observed in Latin America. In Mexico, the prevalence of obesity in children less than 5 years of age increased by more than 25%, from 4.2% in 1998 to 5.3% in 1999 [Rivera et al. 2002] . , 2004] . In Argentina, a relationship was observed between social status and high BP, wherein the prevalence of high BP was twice as high for subjects with less than 7 years of education relative to those with more than 12 years of education (53% and 26%, respectively) [Ministerio de Salud de la Nacion, 2006 ]. This trend also was found in Brazil, where the prevalence of high BP in women with fewer than 8 years of education was more than double that in women with more than 12 years of education (32.8% and 13.6%, respectively) [Ministerio da Saude, 2007] . In Chile, high BP also was more common among people with less education (54.6% of those with basic education versus 21.7% of those with tertiary-level education) [Ministerio de Salud de Chile, 2004] .
Smaller studies have shown a similar inverse relationship between socioeconomic status and high BP. In a study in Region VIII of Chile, the relationship between the prevalence of high BP and socioeconomic level was inversly proportional, with people in the lowest socioeconomic level having the highest level of hypertension (24.5%) [Fasce et al. 2007 ]. Among Mexican adolescents, hypertension was significantly less common among girls attending private urban schools (7%) compared with those in public urban schools (11%), the selection of school type being a surrogate marker of differences in socioeconomic status [Yamamoto-Kimura et al. 2006 ]. Although the inverse relationship between socioeconomic status and high BP appears to be well established, one study in urban Brazil showed a higher rate of hypertension in well-off residential areas compared with less well-off areas [Ala et al. 2004] .
Awareness and control of high BP Assessing the burden of high BP is complicated by the fact that the condition is largely asymptomatic. As a result, many people are unaware of it and thus do not seek treatment. Even in developed countries, rates of awareness of high BP (i.e. BP > 140/90 mmHg) and BP control are far from acceptable. In the US, only 75% of people diagnosed with high BP were aware that they had the condition, and only 37% have their BP controlled [Ong et al. 2007] . In a study conducted in Spain, fewer than 60% of the people surveyed were aware that they had high BP, and only 23% had their BP controlled [Wolf-Maier et al. 2004] .
Awareness tends to be worse in low-and middleincome countries. In poor areas, people generally receive episodic care only and do not receive routine health examinations, such that high BP continues to go undiagnosed in the majority of cases. Moreover, education levels generally are low and, as a result, many people do not understand the adverse consequences of high BP. Healthcare services are already strained, so little (if any) time and money are devoted to awareness campaigns. Only 3.5% of the WHO's budget was spent on chronic disease in 2002, although the organization estimates that it is possible to prevent 80% of heart disease, strokes, and diabetes by eliminating risk factors, most of which are modifiable [Dirks et al. 2006b; WHO, 2005] . Even in the US, 95% of money spent on healthcare is allocated to treatment and only 5% to prevention [Dirks, 2006b] .
Rates of awareness, treatment, and control of BP in many parts of Latin America are grossly inadequate. In Cuba, only 40% of people with hypertension have their BP controlled Ordunez-Garcia et al. 2006 ]. In the 2000 Venezuelan prevalence study [Sulbaran et al. 2000 ], 46% of people were aware that they had high BP, but only 23% of were receiving pharmacologic treatment and only 4.5% had their BP well controlled. In the 2000 National Health Survey in Mexico, 61% of those in whom hypertension was detected were unaware that they had high BP. Only 46% of people with high BP were receiving treatment, and 15% had their BP controlled [Velazquez Monroy et al. 2002] . In the FRIMEX study, 49% of people with high BP were aware that they had it; 73% were receiving treatment, but BP was controlled in only 36% of those being treated (13% of all patients with high BP) [Meaney et al. 2007 ]. In the 2006 Nicaraguan study, 50% of people receiving treatment had their BP controlled, similar to observations in other Latin American countries [Blondin and Lewis, 2007] . Even among patients with high BP attending a university hospital outpatient clinic in Rio de Janeiro, only 27% had their BP controlled to 140/90 mmHg, despite intensive treatment (42% of patients were receiving two and 19% three antihypertensive drugs) [Muxfeldt et al. 2004] . Attending physicians reported an intention to change BP regimens for only 20% of patients with uncontrolled BP. Thus, physicians also need better understanding of the importance of adequate BP control in preventing adverse outcomes.
Progress has been made in improving BP control in some parts of Latin America. For example, in the prevalence study in Region VIII of Chile, the percentage of people who were aware that they had high BP remained the same throughout the study period, but treatment rates increased from 37% to 60% and control rates improved from 8% to 31% [Fasce et al. 2007 ]. This four-fold increase in hypertension control is encouraging, but far from ideal.
It is well known that the long-term treatment of high BP significantly reduces all-cause and cardiovascular mortality [Sytkowski et al. 1996 ]. The observations presented in this section emphasize the need for better services and education of both healthcare providers and patients across Latin America to improve awareness of the importance of controlling BP. Efforts to better understand the factors associated with poor recognition and control of high BP among physicians and patients in the primary care setting are expected to be elucidated from the ongoing Reasons for not Intensifying Antihypertensive Treatment study, an international intervention effort that will include data from three Latin American countries (Argentina, Colombia and Mexico) [Ferrari et al. 2006 ].
Improved patient awareness and better understanding of the risks associated with hypertension also are important for fostering better patient adherence to treatment regimens [Cramer et al. 2008; Thakur et al. 1999] . Poor adherence to medical management is a global problem, and most likely is a greater problem in Latin America than in well-developed countries. For example, among 2029 individuals !65 years of age with diagnosed hypertension who participated in the cross-sectional Mexican Health and Aging Study, 21.5% were not following any of their prescribed treatments for controlling BP; failure to comply with treatment regimens correlated independently with low education levels [Melano-Carranza et al. 2008] . To address the issue of poor compliance, the types of initiatives that work globally should be incorporated into Latin American practice. These include improved patient-physician relationships, patient education on CVD and the consequences of poor BP control, and simplified dosing regimens, including fixed-dose combination therapies [Cramer et al. 2008; Neutel, 2008] .
Hypertension as a risk factor for cardiovascular, cerebrovascular, and renal disease
Cardiovascular disease
High BP is the greatest risk factor for CVD worldwide. Specific risk has been quantified in regions of Latin America. For example, the study of Factores de Riesgo Coronario en America del Sur (FRICAS) was one of the largest epidemiologic studies on cardiovascular risk in this region, and included data from Argentina, Cuba, Mexico and Venezuela [Pramparo, 2002] . Results demonstrated that high BP was the major risk factor for acute MI, such that people with high BP were 2.7 times more likely to experience MI than people with normal BP. The risk increased six-fold for patients who had total cholesterol levels above 240 mg/dl in addition to high BP, and seven-fold for those with high BP who used tobacco [Pramparo, 2002] .
As an attributable risk, high BP consistently accounted for one-third of acute MIs in these countries, whereas the risk attributable to other cardiovascular risk factors was more variable [Ciruzzi et al. 2003 ].
Recent evidence shows that, in Argentina, high BP accounts for 37% of MIs and strokes, and for more than a third of DALYs lost to CVD in 2005 [Rubinstein et al. 2008] . In Colombia, high BP, hypercholesterolemia, and abdominal obesity each accounted for 19% of the risk for coronary events, and the presence of all three risk factors accounted for 41% of the risk [Bautista et al. 2006 ]. Data from the six Latin American countries participating in INTERHEART confirmed the findings of the FRICAS study; high BP was associated with an odds ratio of 2.8 for developing acute MI [Lanas et al. 2007 ] compared with an odds ratio of 2.4 for the non-Latin American countries participating in INTERHEART. In the study of Acute Myocardial Infarction Risk factor Assessment in Brazil (AFIRMAR), high BP was an independent risk factor for acute MI (odds ratio 2.1) [Piegas et al. 2003 ]. The odds ratios for acute MI in patients with high BP have reportedly been even higher in certain countries in Latin America (e.g. 3.72 in Venezuela and 3.67 in Mexico) [Ciruzzi et al. 2003 ].
Cerebrovascular disease
Stroke is another leading cause of death in Latin America. Hypertension and hypertensive arteriopathy are the main risk factors for ischemic and hemorrhagic stroke among Latin Americans. The percentage of strokes attributed to high BP is higher in Latin America than in other continents: 60% to 80% of Latin American stroke victims have high BP [Camargo et al. 2005 ]. In addition to the traditional risk factors, endemic disease and regional tropical risk factors unique to Latin America have a major impact on stroke risk [Camargo et al. 2005] . In 2000, mortality due to cerebrovascular accident was two-to four-fold higher in Latin America (except in Puerto Rico) than in North America ( Figure 5 ) [Rodriguez et al. 2006 ]. In addition to risk factors unique to Latin America, the higher rate of stroke has been attributed to inadequate medical treatment of high BP and to changes in diet and lifestyle associated with rural-to-urban migration [Rodriguez et al. 2006; Camargo et al. 2005 ].
Renal disease
The kidneys are affected by end-organ damage related to hypertension. In Latin America, chronic kidney disease usually is caused by diabetes, high BP, or glomerulonephritis [Depine and Calderon, 2006 ]. The profile of renal pathology appears to be somewhat different in Latin America than in other countries; most notably, the rate of glomerulonephritis is higher in Latin America because of tropical parasitic diseases [Zatz et al. 2003 ]. In Rio de Janeiro, 11% of patients with high BP attending a university hospital outpatient clinic had nephropathy [Muxfeldt et al. 2004 ]. The prevalence of chronic kidney disease and end-stage renal disease whether related to high BP or other causes is largely unknown across Latin America because these conditions are underdiagnosed [Zatz et al. 2003 ]. In a recent workshop involving various Latin American health ministries, scientific and medical societies, and PAHO, it was noted that the true prevalence of kidney disease in Latin America is unknown [Depine and Calderon, 2006 ].
Cost of high BP and cost-effectiveness of treatment in Latin America
Much evidence shows that CVD has important economic consequences important for the individual and his/her family, but also potentially important for the economy at large. At the same time, there are severe gaps in the evidence that call for more research into the economic consequences of CVD, in particular for developing countries. The costs associated with high BP are substantial, given that it is a leading cause of cardiovascular and cerebrovascular morbidity and mortality. In a cost analysis conducted in Mexico, the costs associated with high BP were estimated at $2.5 billion US annually for 20052007, which was 6.8% of the total expenditure on health [Arredondo and Zuniga, 2006 ]. Of the $1.3 billion in direct costs, $743 million (57%) was associated with the treatment of complications, such as nephropathy (55% of the total), nonfatal MI (25%), and nonfatal stroke (20%) [Arredondo and Zuniga, 2006 ]. Of the $1.2 billion in indirect costs, 15% was attributed to mortality and the remainder to permanent and temporary disability relating to complications. These costs are expected to rise in tandem with the anticipated increase in prevalence of high BP.
The disproportionate cost burden for treating complications and the indirect costs of mortality and disability, underscore the urgent need for improved healthcare services and for education on high BP and its treatment, with greater focus on preventive measures (less expensive than treatments for complications).
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associated with an incremental cost-effectiveness ratio (ICER) of $4500 ARS (approximately US$1500 at the current exchange rate) per DALY saved (Rubinstein, A., personal communication, 2008) . WHO considers interventions to be very cost-effective if the ICER is lower than the gross national product (GNP) per head, costeffective if the ICER is less than three times the GNP per head, and not cost-effective if the ICER is above three times the country's GNP per capita [Baltussen et al. 2002] 1975 1980 1985 1990 1995 2000 2005 Calendar years Deaths per 100 000 1975 1980 1985 1990 1995 2000 2005 Calendar years Deaths per 100 000 1975 1980 1985 1990 1995 2000 2005 Calendar years 0 1970
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. mass-media health education with respect to high BP, cholesterol, and body mass . legislation or voluntary agreements with the food industry to lower the salt content of processed foods . population-wide reductions in salt intake.
Personal health-service interventions included detection and pharmacologic treatment of high BP and hypercholesterolemia with generic drugs. All interventions were highly cost-effective (Table 4) , with better ratios for personal than nonpersonal interventions. The best choices in terms of cost-effectiveness, and the incremental gain from moving from one intervention to another, are shown in Figure 6 . If extreme resource constraints exist, nonpersonal interventions should be used first, followed by a combination approach to reduce absolute risk and provide the greatest gains in health ].
Another cost-effectiveness analysis used a Markov model to compare primary prevention using a combination regimen of aspirin, a calcium channel blocker, an angiotensin-converting enzyme (ACE) inhibitor, and a statin (all widely available as generic products), and secondary prevention with aspirin, a beta-blocker, an ACE inhibitor and a statin in poor-resource settings [Gaziano, 2006] . Three groups of patients were considered: those with CVD, those without previous disease but with 10-year absolute risks above 5%, and those over 55 years of age without additional risk factors. In Latin America, the lifetime risk of death from CVD with no treatment was 34%, and the risk was reduced with all regimens considered in the cost-effectiveness model. The primary prevention strategy of treating patients with a 10-year absolute risk of at least 5% resulted in the greatest benefit, halving the lifetime risk of death. The incremental cost-utility ratio (USD per QALY gained) was US$388 for the secondary regimen. For primary treatment, the incremental cost-utility ratios (in USD) were $881, $930, and $1219 for absolute risk reductions of more than 25%, 15% and 5%, respectively [Gaziano et al. 2006 ]. The Commission for Macroeconomics and Health has recommended that any intervention costing less than triple a country's per-capita gross domestic product for QALY gained, be regarded as cost-effective [WHO, 2001] .
Projected population changes in Latin America
The average life expectancy in Latin America has increased from 52 years in 1950 to 72 years currently, and is expected to increase to 79 years by 2050 [Palloni et al. 2002] . Increased life expectancy reflects improved living standards and reductions in rates of infectious and communicable diseases. Increased life expectancy also increases the overall population and the proportion of people over 65 years of age (Figure 7) , who have the greatest risk for high BP and CVD. Modernization and associated lifestyle changes (less physical activity and heavier reliance on prepackaged, high-calorie, high-fat foods) are expected to increase the prevalence of high BP and other cardiovascular risk factors, and the corresponding socioeconomic burden. An increase of 148% in the prevalence of diabetes in Latin America from 2000 to 2030 has already been noted [Wild et al. 2004 ].
Future goals
Prevention and treatment are the most obvious strategies for reducing long-term chronic disease. On the basis of attributable risk analyses, 2030% of all coronary events in the next 10 years could be prevented by treating and/or preventing high BP [Bautista et al. 2006; Ciruzzi et al. 2003 Figure 6 . Yearly cost and effectiveness of treatments for hypertension and cholesterol in Latin America. The solid lines connect the most cost-effective points. The steeper the slope, the more expensive the intervention. See Table 3 for explanation of terms. Reprinted from The Lancet, 361, Murray and Lopez, 717725, 2003 , with permission from Elsevier.
Early detection and treatment of high BP also would reduce the long-term burden of the disease. However, healthcare resources across Latin America are scarce, and current systems focus on treatment rather than prevention of disease. As has been shown in this report, BP is adequately controlled in very few people with high BP, even those receiving pharmacologic treatment. Several health-economic analyses have clearly shown that preventing and treating high BP would be far less expensive than dealing with the longer-term morbidity and mortality resulting from failure to prevent and treat. Indeed, the analyses show that treating high BP would be highly cost-effective in preventing chronic disease in Latin America. Therefore, concerted efforts must be made to allocate appropriate funds and resources for improved healthcare. As a minimum, healthcare systems will need to develop the capacity to deal with the increased burden of chronic disease imposed by high BP in the future. A key factor is to demonstrate the value (health and economic value) to government and third-party payers of investing in the prevention and control of high BP.
Significant efforts already have been made to assist healthcare providers in Latin America. The WHO has published simplified risk prediction charts for use in low-and middle-income countries that do not have the basic infrastructure to support resource-intensive risk-prediction tools [Mendis et al. 2007 ]. In addition, international and regional nephrology societies have collaborated to devise strategies to prevent chronic kidney disease in Latin America [Dirks et al. 2006a ]. The Inter-American Society for Hypertension is a non-profit organization with specific efforts to promote understanding, prevention, and control of hypertension and vascular diseases, particularly in Latin America. These efforts are a start, but additional involvement of local experts to encourage dissemination, acceptance, and implementation of the guidelines in Latin American is needed [Burlando et al. 2004 ].
Latin America is a culturally, socioeconomically, geographically and ethnically diverse region, and different healthcare models are needed for different areas. The impact of high BP in Latin America can be reduced, but efforts must be started now. Local governments, international organizations, the private sector, and society as a whole must collaborate to improve the cardiovascular health of Latin Americans, now and for the future. Changes in the core policy of the area are needed (Table 5) .
Conclusion
High BP is a burgeoning healthcare problem worldwide, but its prevalence and consequences are particularly dire in low-and middle-income countries. Although the US has benefited from a 60% reduction in coronary heart disease and cerebrovascular disease over the past 30 years, similar reductions have not been achieved consistently in Latin America ( Figure 5 ) [Rodriguez et al. 2006 ]. The increasing prevalence of high BP and chronic diseases, together with expected increases in population growth, presage their growing threat to Latin American economies.
Although this report provides a comprehensive overview of the burden of high BP across Latin America, it alone cannot bring about change. These observations warrant a call to action for improved control of high BP and other cardiovascular risk factors across Latin America and the acceptance and institution of core policy changes (Table 5 ) are a key start to this action. 
Recommendations
Core policy 1 Demonstrate to regional policymakers the benefits of detection and control of high BP in reducing health consequences, such as the cardiovascular and renal burden of disease in Latin America, so that they recognize high BP as a global epidemic and a major public health priority in Latin America 2 Empower and train family doctors, clinicians, nurses, and other health professionals in the primary care setting to provide first-contact care for detection, diagnosis, treatment, and control of high BP 3 Provide people with access to and coverage of evidence-based interventions including effective drugs against high BP 4 Support campaigns directed at early detection and management of high BP, and other cardiovascular risk factors 5 Implement country-wide campaigns to promote education and awareness of the risks of high BP, as well as the means to prevent and treat it 6 Promote and support education directed toward the implementation of healthy lifestyles, focused primarily on children and their teachers 7 Promote educational campaigns for self-detection and prevention of cardiovascular risk factors, such as obesity, smoking, lack of exercise, and unhealthy diet Additional treatment 1 Encourage drug use based on clinical-and cost-effectiveness, acceptability, and affordability, acknowledging the resource-constrained budgets in most Latin American countries 2 Integrate management of high BP within the context of other cardiovascular risk factors that also may be present in hypertensive patients 3 Encourage behavioral tactics to improve treatment compliance and adherence 4 Demonstrate to government officials and third-party payers the cost/utility benefits of hypertension prevention, identification, and treatment campaigns Additional research 1 Include patients from Latin America in large, long-term, clinical-outcome and epidemiologic studies to improve clinical outcomes in specific regional context 2 Support funding for Latin American-oriented research programs, including patient-oriented acceptance and compliance issues within the context of Latin America
